Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
11 08 2022
Historique:
pubmed: 27 7 2022
medline: 13 8 2022
entrez: 26 7 2022
Statut: ppublish

Résumé

PKMYT1 is a regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with

Identifiants

pubmed: 35880755
doi: 10.1021/acs.jmedchem.2c00552
pmc: PMC9837800
mid: NIHMS1859502
doi:

Substances chimiques

Membrane Proteins 0
Protein Kinase Inhibitors 0
Protein-Tyrosine Kinases EC 2.7.10.1
PKMYT1 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

10251-10284

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM124165
Pays : United States
Organisme : CIHR
Pays : Canada

Références

Chem Rev. 2016 Oct 12;116(19):12564-12649
pubmed: 27689804
J Med Chem. 2014 Aug 14;57(15):6834-44
pubmed: 25076195
J Med Chem. 2006 Nov 16;49(23):6819-32
pubmed: 17154512
Xenobiotica. 2012 Aug;42(8):808-20
pubmed: 22385482
J Med Chem. 2001 Nov 8;44(23):3965-77
pubmed: 11689083
Molecules. 2017 Nov 23;22(12):
pubmed: 29168755
Mol Cell Proteomics. 2012 Sep;11(9):745-57
pubmed: 22700489
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Chemistry. 2019 Aug 27;25(48):11228-11232
pubmed: 31241789
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Elife. 2013 Sep 10;2:e01456
pubmed: 24040512
Eur J Med Chem. 2021 Mar 15;214:113189
pubmed: 33540354
J Med Chem. 2021 Aug 12;64(15):11129-11147
pubmed: 34291633
Molecules. 2004 Mar 31;9(4):223-31
pubmed: 18007426
Methods. 2011 Sep;55(1):94-106
pubmed: 21821126
Oncogene. 2013 Oct;32(40):4778-88
pubmed: 23146904
J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):245-51
pubmed: 11318421
Org Biomol Chem. 2015 Oct 28;13(40):10122-6
pubmed: 26377704
J Med Chem. 2011 Oct 27;54(20):7005-22
pubmed: 21848318
Cell Chem Biol. 2018 Feb 15;25(2):206-214.e11
pubmed: 29174542
Cancer Res. 1999 Dec 15;59(24):6145-52
pubmed: 10626805
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9282-9287
pubmed: 30150405
Eur J Med Chem. 2020 Aug 15;200:112319
pubmed: 32446036
Nature. 2022 Apr;604(7907):749-756
pubmed: 35444283
Cancer Res. 2011 Feb 15;71(4):1385-95
pubmed: 21303981
Adv Exp Med Biol. 2017;1042:527-547
pubmed: 29357072
Cell Rep Med. 2021 Sep 23;2(9):100394
pubmed: 34622231
Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8
pubmed: 17600705
ACS Chem Neurosci. 2015 Jun 17;6(6):845-54
pubmed: 25856736
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Biochemistry. 2007 Jan 16;46(2):350-8
pubmed: 17209545
Assay Drug Dev Technol. 2009 Dec;7(6):560-72
pubmed: 20105026
PLoS One. 2011;6(6):e19923
pubmed: 21698148

Auteurs

Janek Szychowski (J)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Robert Papp (R)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Evelyne Dietrich (E)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Bingcan Liu (B)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Frédéric Vallée (F)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Marie-Eve Leclaire (ME)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Jimmy Fourtounis (J)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Giovanni Martino (G)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Alexander L Perryman (AL)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Victor Pau (V)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.

Shou Yun Yin (SY)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Pavel Mader (P)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.

Anne Roulston (A)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Jean-Francois Truchon (JF)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

C Gary Marshall (CG)

Repare Therapeutics, 1 Broadway, 15th Floor, Cambridge, Massachusetts 02142, United States.

Mohamed Diallo (M)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Nicole M Duffy (NM)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Rino Stocco (R)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Claude Godbout (C)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Alexanne Bonneau-Fortin (A)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Rosie Kryczka (R)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Vivek Bhaskaran (V)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Daniel Mao (D)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.

Stephen Orlicky (S)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.

Patrick Beaulieu (P)

OmegaChem Inc., 480 Rue Perreault, Saint-Romuald, QC G6W 7V6, Canada.

Pascal Turcotte (P)

AdMare BioInnovations, 7171 Frederick-Banting, Montréal, QC H4S 1Z9, Canada.

Igor Kurinov (I)

Department of Chemistry and Chemical Biology, Cornell University, NE-CAT, Argonne, Illinois 60439, United States.

Frank Sicheri (F)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.
Departments of Biochemistry and Molecular Genetics, University of Toronto, Ontario M5S 1A8, Canada.

Yael Mamane (Y)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Michel Gallant (M)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

W Cameron Black (WC)

Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH